PubMed Health⌕ Search

PubMed · 10420421

Chemotherapy medication errors: descriptions, severity, and contributing factors.

Abstract

PURPOSE/OBJECTIVES: To expand the limited body of knowledge of medication errors involving chemotherapy. DESIGN: Exploratory, descriptive. SAMPLE: 160 (26%) of 620 randomly selected Oncology Nursing Society members employed in direct patient-care positions and 26 nonmembers with chemotherapy administration responsibilities employed in different settings. METHODS: Mailed investigator-developed questionnaire containing 24 demographic and open-ended questions. MAIN RESEARCH VARIABLES: Nurses' descriptions of the nature and severity of chemotherapy medication errors. FINDINGS: Chemotherapy medication errors were reported to have occurred in the workplace of 63% of the respondents, and 140 errors were described. Errors included under- and overdosing, schedule and timing errors, wrong drugs, infusion-rate errors, omission of drugs or hydration, improper preparation of drugs, and chemotherapy given to the wrong patients. Stress, understaffing, lack of experience, and unclear orders were cited as factors believed to contribute to the occurrence of the errors. Most of the errors were reported internally, but only 3% were known to be reported to national reporting databases or drug manufacturers. CONCLUSIONS: Chemotherapy medication errors are not uncommon and infrequently are reported externally to databases or manufacturers. IMPLICATIONS FOR NURSING PRACTICE: Risk management strategies to promote safe chemotherapy administration include comprehensive chemotherapy administration training, adherence to basic principles of medication administration, and adequate staffing. Oncology nurses need to know how and when to report chemotherapy medication errors to national databases and drug manufacturers.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

L Schulmeister. 1999. Chemotherapy medication errors: descriptions, severity, and contributing factors.. https://pubmed.ncbi.nlm.nih.gov/10420421/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Deep generative neural network for accurate drug response imputation.

Drug response differs substantially in cancer patients due to inter- and intra-tumor heterogeneity. Particularly, transcriptome context, especially tumor microenvironment, has been shown playing a significant role in shaping the actual treatment outcome. In this study, we develop a deep variational autoencoder (VAE) model to compress thousands of genes into latent vectors in a low-dimensional space. We then demonstrate that these encoded vectors could accurately impute drug response, outperform standard signature-gene based approaches, and appropriately control the overfitting problem. We apply rigorous quality assessment and validation, including assessing the impact of cell line lineage, cross-validation, cross-panel evaluation, and application in independent clinical data sets, to warrant the accuracy of the imputed drug response in both cell lines and cancer samples. Specifically, the expression-regulated component (EReX) of the observed drug response achieves high correlation across panels. Using the well-trained models, we impute drug response of The Cancer Genome Atlas data and investigate the features and signatures associated with the imputed drug response, including cell line origins, somatic mutations and tumor mutation burdens, tumor microenvironment, and confounding factors. In summary, our deep learning method and the results are useful for the study of signatures and markers of drug response.

Antineoplastic Agents↗

Favorable response of intraommaya topotecan for leptomeningeal metastasis of neuroblastoma after intravenous route failure.

A 3-year-old male, diagnosed with stage 4 neuroblastoma, developed recurrent leptomeningeal metastasis after multi-modality treatment including multi-agent chemotherapy, surgery, high dose chemotherapy plus stem cell rescue, cis-retinoic acid and intravenous (IV) topotecan. He then received intraommaya (IO) topotecan three times weekly (maximum dose; 0.4 mg). A complete response was achieved by a resolution of malignant cells in cerebrospinal fluid and resolution leptomeningeal enhancement by brain MRI. Treatment toxicities included low-grade fever and minimal headache. The duration of treatment response from IO topotecan was 18 weeks. The survival time from CNS recurrence in this patient was 13 months. We suggest IO topotecan be considered for neoplastic meningitis of tumors with known sensitivity to topotecan.

Antineoplastic Agents↗

Mobilization of Ph chromosome-negative peripheral blood stem cells in a child with chronic myeloid leukemia after imatinib-induced complete molecular remission.

Chronic myelogenous leukemia (CML) is rare in the pediatric population. Allogeneic stem cell transplant remains the only curative therapy; however, identifying a fully matched donor is not always possible. Imatinib mesylate has been shown to induce hematologic and cytogenetic response in adults and children with CML. We describe a child who achieved molecular remission with imatinib mesylate. BCR-ABL negative peripheral blood stem cells (PBSC) were successfully collected after mobilization with filgrastim.

Antineoplastic Agents↗